Advancing Forensic Accuracy with Post-Mortem Toxicology Testing Solutions in Europe

Advanced toxicology solutions improve forensic accuracy, substance detection, and investigative efficiency across European laboratories.

Life Sciences Review | Monday, August 10, 2026

Post-mortem toxicology testing is very important in science, as it helps investigators figure out if drugs, alcohol, poisons or other toxic substances caused someone's death. In Europe, there's a growing need for forensic analysis, following rules and faster investigations. It is leading to improvements in post-mortem toxicology testing, and these improvements are crucial for labs, medical examiners, police, hospitals and courts.

Figuring out how and why someone died can be very complex and is true in cases of suspected overdose, poisoning or unexplained deaths. Old toxicology methods involve a lot of work, like preparing samples and processing them in the lab. There are challenges in interpreting results because the body changes after death. Modern post-mortem toxicology testing uses instruments, automated processes and better sample handling.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

Role of Advanced Toxicology Solutions

Changes in the body after death can affect the quality of samples and make it hard to interpret test results. In Europe, where forensic standards are very strict, these technological advancements are making investigations more trustworthy. As forensic science evolves, post-mortem toxicology testing is becoming a part of investigating deaths based on evidence. Toxicology testing is important for forensic professionals to figure out what substances were present in a person's body.

Modern testing technologies help labs detect and measure a range of substances more accurately. It enables professionals to identify compounds that were previously hard to detect in complex toxicology cases involving multiple substances. Automation is greatly improving how efficiently labs work. Preparing samples, extracting substances and processing data used to require a lot of effort. Automated systems help reduce mistakes, improve consistency and speed up test results.

Toxicology labs need to screen for a range of substances, including pharmaceuticals, illicit substances, industrial chemicals and environmental toxins. Advanced testing platforms support comprehensive analysis of these substances. Toxicology results often need to be evaluated alongside evidence, such as pathology findings and medical history. Digital analytics and decision-support systems help forensic experts make sense of data more effectively.

Standardised workflows, testing protocols and secure chain-of-custody systems strengthen the reliability of evidence and support confidence in the judicial system. Labs need to be able to handle fluctuating case volumes. Flexible testing solutions help forensic institutions maintain performance under growing demand while preserving accuracy. By improving accuracy, automation and reliability, advanced toxicology solutions are strengthening forensic investigation capabilities across Europe.

Importance of Innovative Toxicology Approaches

The need for post-mortem toxicology testing solutions is getting bigger because of public health problems, more complicated forensic investigations and higher expectations for scientific accuracy in legal cases. Advanced toxicology solutions are helping forensic labs provide accurate and reliable results. People misusing drugs, taking medicines and being exposed to new synthetic substances have made toxicology more complex, so better testing helps to support accurate investigations.

New psychoactive substances are making things harder. The substances can be tough to find using testing methods, so better and more flexible toxicology screening solutions are important. Learning from toxicology can give important information about substance use, poisoning risks and health concerns, which can help to prevent problems and make good policy decisions. Courts and regulatory systems are expecting scientific proof, so reliable toxicology results for criminal investigations, insurance cases, work-related cases and court proceedings.

In Europe, forensic labs are working together, which is changing the standards. They are sharing ideas and regulatory expectations, which encourages labs to use better analytical solutions that work across different areas. Solutions that make workflows without hurting quality are becoming more valuable. The mix of forensic cases, high legal expectations, and public health priorities keeps driving up the need for advanced toxicology services. Post-mortem toxicology testing solutions are necessary for reasons, including substance-related deaths and public health monitoring.

Exploring the Future of Toxicology Testing After Demise

The field of post-mortem toxicology testing is moving towards getting results, getting more information and using more data to do forensic analysis. AI can help identify patterns of substances, find things that do not seem right, and make it easier to understand cases. Post-mortem toxicology testing solutions are getting better, which helps with cases and forensic investigations. Forensic toxicologists are essential for understanding results, in context, giving expert testimony and making scientific judgments.

New and better analytical platforms will keep making it possible to detect small amounts of substances and new compounds. It will make it easier to find substances that are hard to detect and new substances that are emerging. Automation can help with processing samples, keeping track of samples and making reports automatically, which can help laboratories get results faster and be more consistent. Post-mortem toxicology testing systems will connect with pathology, case management and investigative platforms to support a complete analysis of cases.

Post-mortem toxicology testing will keep making science in Europe better by being more precise, being able to analyse more things, and making workflows more efficient. The focus will stay on delivering evidence that supports reliable investigations and informed judicial outcomes. Post-mortem toxicology testing is a forensic capability that strengthens investigative accuracy, scientific confidence and evidentiary reliability.

More in News

Deuterium Drug Discovery needs Chemistry that can Carry Patent Risk

Deuterium chemistry creates an unusual buying problem for pharmaceutical research teams. The science is no longer speculative, yet the specialist base remains thin. A program may begin with a narrow request for a deuterated version of a known molecule, but the commercial question usually sits elsewhere. Which positions can be exchanged, which structures can be protected, which analogs are worth testing and which supplier can make the requested compound without turning the work into a prolonged research detour? That gap matters because deuteration is not simply another intermediate purchase. Specialty chemical buyers can often compare vendors on catalog depth, lead time, quality paperwork and price. Drug-discovery teams need a different kind of proof. Selective exchange across difficult sites becomes the first filter. Documentation must also stand up in an IP file. The scientific team has to move between route design and practical sample delivery without treating each new molecule as a chemistry experiment with uncertain boundaries. Patent pressure is becoming part of the buying logic. A company may have no immediate plan to develop a deuterated drug, yet still need deuterated analogs to protect an original small-molecule program from later substitution. That creates a practical service need around site coverage, synthesis reliability, purity control and speed of response. The vendor that can make only the easiest analog may help with a single study but leave exposed positions untouched. The more useful partner can map deuteration across the relevant structure and turn that map into compounds suitable for filing support or early biological review. Discovery teams also need restraint. Deuteration can affect metabolism, exposure window, dosing behavior and metabolite profile, but not every molecule justifies a broad program. The stronger evaluation is not whether a supplier speaks fluently about isotope chemistry. It is whether it can narrow the practical field before chemistry spend expands. Judgment is needed around reachable sites and substitutions that may matter. Some requests are better kept as patent defense rather than development work. Poor screening wastes time in a market where chemistry talent is already scarce. “For executives evaluating this narrow field, the stronger reason to consider CombiPhos Catalysts is not catalog breadth alone. It is the ability to approach deuterated compounds as selective chemistry, patent protection work, analog design and early drug-discovery support.” The same discipline applies to supply. Deuterated compounds tied to pharmaceutical research carry different expectations from general research chemicals. Buyers need confidence in batch identity, purity thresholds, repeatability and communication around difficult synthesis steps. They also need candor when a structure is unlikely to justify a full program. A supplier that only sells molecules may complete an order. A partner that understands deuteration as a discovery and IP tool can help the research team decide what should be made. CombiPhos Catalysts fits this buying logic because its work is centered on catalytic deuterium chemistry rather than general contract synthesis. Its scope includes deuterium drug discovery through hydrogen-deuterium exchange and C-D cross-coupling chemistry, supported by a background in homogeneous catalysis and pharmaceutical intermediates. For executives evaluating this narrow field, the stronger reason to consider CombiPhos Catalysts is not catalog breadth alone. It is the ability to approach deuterated compounds as selective chemistry, patent protection work, analog design and early drug-discovery support. This makes CombiPhos Catalysts a premier choice where the buyer needs difficult deuteration handled with technical judgment, not just sample supply. ...Read more

Choosing a PVP Manufacturer for Formulation Risk

PVP buying rarely fails at the purchase order. It fails earlier, when an excipient is treated as a commodity line item while the formulation depends on subtle polymer behavior. A povidone grade that looks acceptable on a specification sheet can still affect solubility, flow, binding performance, impurity exposure, particulate control or finished-dose consistency. For pharmaceutical teams, the risk is not only whether material arrives. It is whether each lot behaves predictably inside a process that has already been validated. Procurement cycles in pharmaceutical excipients have grown less forgiving because quality files, audit readiness, change control records and supply assurance now sit close together. Buyers cannot separate price from technical support for long. A low-cost supplier that cannot explain polymer performance under real manufacturing conditions creates hidden work for formulation teams and regulatory staff. A manufacturer with deeper chemistry knowledge can shorten that work by helping customers understand why a grade behaves differently under heat, compression, moisture or mixing stress. That support matters most when a PVP product must do more than meet compendial expectations. It must solve a formulation problem without forcing a costly process detour. Manufacturing control is another dividing line. Automated production records, tighter process monitoring, controlled data capture and fewer manual handoffs give buyers a better basis for comparing suppliers beyond certificate language. Consistency is not an abstract preference in this field. It affects validation confidence, complaint handling, audit discussions and batch release timing. The supplier’s plant discipline must also show in contamination prevention and particle management, since these are practical concerns for material that enters medicine, not secondary housekeeping details. [QUOTE1_Replace] Supply continuity deserves the same scrutiny. Global buyers may accept overseas production, but they often cannot accept distant inventory. Long lead times, port disruption, quality review delays and sudden allocation pressure can turn an approved material into a production bottleneck. Local warehousing, distributor competence, direct technical support and regional regulatory familiarity therefore become part of the product’s real cost. The stronger partner keeps material closer to use points and gives buyers direct technical access when a plant or quality unit needs a fast answer. Good PVP selection also depends on the supplier’s willingness to work past the catalog. Povidone chemistry serves different functions across dosage forms and adjacent markets, but pharmaceutical use places a sharper burden on evidence and control. Buyers should look for a manufacturer that can connect polymer structure with formulation behavior, adjust material attributes for the intended process and respond without forcing every issue through a slow hierarchy. This combination reduces avoidable trial work while keeping accountability visible. Boai NKY Pharmaceuticals fits this buying logic because it pairs PVP manufacturing scale with formulationfacing technical depth. Its relevant excipient scope includes KoVidone and PolyKoVidone products, supported by application research, automated production control, regulatory quality systems and global supply planning. The company’s model is especially useful where buyers need stable global supply without losing access to decision-makers. Managed warehousing and technically capable distributor relationships help reduce distance between Chinese manufacturing and local delivery. For executives evaluating PVP product manufacturers, Boai NKY Pharmaceuticals is a restrained recommendation because it links material science, production consistency, supply planning and responsive support in one supplier relationship ...Read more

Cell Therapy Developers Put Manufacturing Strategy Earlier in the Pipeline

Cell therapy product development is becoming more manufacturing-led as companies recognize that clinical promise can weaken if process design is not addressed early. Developers are moving beyond a research-first mindset and placing greater attention on scalability, product consistency, release testing and manufacturing evidence before late-stage trials. The market context supports this shift. The global cell therapy manufacturing market is estimated at USD 6.51 billion in 2026 and is projected to reach USD 17.65 billion by 2033, according to Coherent Market Insights. Growth is being shaped by demand across autologous and allogeneic therapies, along with development activity in oncology, musculoskeletal conditions, cardiovascular disease, neurological conditions and other areas. For developers, the manufacturing process looks very different depending on the type of therapy being produced. Autologous therapies require each patient's cells to be collected, processed and returned through a carefully coordinated, individualized workflow. Allogeneic therapies, by contrast, are designed for larger-scale production but bring their own challenges around batch manufacturing and immune compatibility. In both cases, success depends on building manufacturing processes that are reliable enough to support clinical development while remaining practical to scale as therapies move toward commercialization. The problem often appears when early research methods are carried too far into development. Manual steps may work in a small study, but become difficult to reproduce later. A release assay may be acceptable for early-stage work but insufficient for a broader program. Raw material variation can also affect performance if it is not understood early. Regulators are placing more attention on chemistry, manufacturing and controls. The FDA issued final guidance in May 2026 on CMC flexibilities for human cellular and gene therapy products being developed for biologics license applications. The guidance describes how the agency applies flexibility to CMC requirements under BLA development. Developers still need to show that the product can be made consistently and that critical quality attributes are understood. Process changes during development must be justified and documented. Sponsors that wait too long to define their manufacturing strategy may face comparability questions that slow progress. Technology is also changing the development environment. At BIO 2026, cell and gene therapy companies discussed using AI and data systems to improve manufacturing work, pointing to a sector where digital tools are becoming more relevant to production learning. The business implication is clear. Cell therapy product development is no longer only about biology and clinical response. It is also about whether a company can build a repeatable product pathway. The next phase will favor developers who treat manufacturing as part of product identity from the start. In cell therapy, a strong clinical idea must be supported by a process that can survive scale, scrutiny and real patient delivery. ...Read more

Autologous and Allogeneic Models Push Cell Therapy Toward Different Development Paths

Cell therapy product development is becoming more segmented as autologous and allogeneic products place different demands on design, manufacturing and commercialization. Developers can no longer discuss the sector as one uniform category. Product strategy depends heavily on whether cells come from the patient or from a donor source. Autologous therapies are often built around individualized production. A patient’s own cells are collected, processed and returned as a therapy. This model can create a strong biological fit, but it also places pressure on scheduling, chain of identity, release timelines and site coordination. Every patient-specific batch becomes both a treatment and a manufacturing event. Allogeneic therapies take a different approach. Instead of using each patient's own cells, they rely on donor-derived or engineered cells that can be produced in larger batches and supplied to more patients. This model has the potential to improve access and make therapies more widely available, provided quality, immune compatibility and long-term performance are carefully managed. At the same time, it brings its own set of challenges, including how cells are sourced, how consistently they can be expanded during manufacturing, how they are stored and how different patients may respond to the treatment. Industry analysis from Thermo Fisher Scientific’s Patheon unit notes that autologous therapies require individualized handling because each treatment is tailored to a patient’s cells, while allogeneic therapies must ensure consistent quality and address immune compatibility across recipients. These differences influence product development from the very beginning. For autologous therapies, developers often concentrate on coordinating the entire vein-to-vein process, including logistics, site readiness, rapid release testing and making sure each patient's cells move through the system efficiently. Developers of allogeneic therapies face a different set of priorities, with greater attention on master cell banks, consistency between production batches, inventory management and large-scale quality control. Each approach comes with its own operational challenges, costs and risks that need to be managed throughout development. Manufacturing partners are therefore becoming more specialized. A partner supporting allogeneic production may need scale-up expertise and robust batch release processes. Developers must choose partners based on model fit, not general cell therapy experience alone. Digital systems are becoming important in both pathways. Developers need data continuity from cell collection through manufacturing and administration. Gaps in records can create delays and weaken confidence. Better data handling can support quality review and long-term learning across batches or patient cases. The future of cell therapy product development will likely involve both models advancing in parallel. Autologous and allogeneic approaches solve different problems and face different barriers. The companies best positioned will be those that align biology, manufacturing design, clinical planning and commercial delivery around the specific therapy model they are building. ...Read more

Specials

Advancing Forensic Accuracy with Post-Mortem Toxicology Testing Solutions in Europe

Advanced toxicology solutions improve forensic accuracy, substance detection, and investigative efficiency across European laboratories.